The bidirectional relationship between chronic kidney disease and atrial fibrillation does not occur in elderly female outpatients

Bociek, Arkadiusz; Bielejewska, Ada; Bociek, Martyna; Dereziński, Tadeusz; Jaroszyński, Andrzej

doi:10.5114/ms.2019.88415

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Impaired renal function is an acknowledged risk factor of thrombus formation, stroke, systemic embolism, and bleeding events. Data showed that NOACs would reduce the risk of stroke or systemic embolism and major bleeding concerning different levels of renal function [ 30 – 32 ]. In the present study, it was shown that higher eGFR predisposes the choice of NOACs.…”

Section: Discussionmentioning

confidence: 99%

Trends in Stroke Prevention between 2014 and 2018 in Hospitalized Atrial Fibrillation Patients

Bielecka

Gorczyca

Jelonek

et al. 2021

Cardiology Research and Practice

View full text Add to dashboard Cite

In recent years, significant changes in stroke prophylaxis in patients with atrial fibrillation (AF) have been observed. Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used in the prevention of thromboembolic complications in patients with AF. The aim of the study was to evaluate recommended stroke prophylaxis in patients with AF and to identify predictors of using NOACs in patients treated with anticoagulant therapy. The present study was a retrospective, observational, single-center study which included consecutively hospitalized patients in the reference cardiology center from January 2014 to December 2018. In the study group of 4027 patients with AF, to prevent thromboembolic complications, OACs were used in 3680 patients (91.4%), an antiplatelet drug(s) was used in 124 patients (3.1%), and 223 patients (5.5%) did not undergo any thromboembolic event prevention. In the group of 3680 patients treated with OACs, 2311 patients (62.8%) received NOACs and 1639 patients (37.2%), VKAs. Independent predictors of the use of NOACs were age (OR, 1.02; 95% CI, 1.01–1.03; P < 0.001 ), a previous thromboembolic event (OR, 1.29; 95% CI, 1.01–1.65; P = 0.04 ), nonpermanent AF (OR, 1.61; 95% CI, 1.34–1.93; P < 0.001 ), and eGFR (OR, 1.22; 95% CI, 1.02–1.46; P = 0.03 ). Between 2014 and 2018, an increase of patients treated with OACs, mainly with NOACs, was observed. Age, past thromboembolic complications, nonpermanent AF, and preserved renal function determined the choice of NOACs.

show abstract

Section: Discussionmentioning

confidence: 99%